Revaprazan HCl 178307-42-1

簡要描述：Revaprazan HCl 178307-42-1
Revaprazan Hydrochloride is the hydrochloride salt form of a lipophilic, weak base with potassium-competitive acid blocking (P-CAB) activity.

產(chǎn)品型號：abs47028035
廠商性質(zhì)：生產(chǎn)廠家
更新時(shí)間：2026-01-14
訪問量：734

產(chǎn)品咨詢聯(lián)系我們

產(chǎn)品分類

Product Category

生化試劑

其它生化試劑植物提取物碳水化合物生物緩沖劑熒光探針與染料表面活性劑酶&輔酶&酶底物蛋白質(zhì)組學(xué) 動(dòng)植物激素小分子化合物生化檢測試劑盒逆行示蹤劑抗生素核苷&核苷酸多肽

查看全部

相關(guān)文章

詳細(xì)介紹

品牌	absin	CAS	178307-42-1
分子式	C22H24ClFN4	純度	99%
分子量	398.9	貨號	abs47028035
規(guī)格	2mg	供貨周期	現(xiàn)貨
主要用途	is the hydrochloride salt form of a lipo	應(yīng)用領(lǐng)域	化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合

Revaprazan HCl 178307-42-1

產(chǎn)品描述
描述	Revaprazan Hydrochloride is the hydrochloride salt form of a lipophilic, weak base with potassium-competitive acid blocking (P-CAB) activity. Revaprazan concentrates highly in the gastric parietal cell canaliculus and on entering this acidic environment is instantly protonated and binds competitively and reversibly to the potassium binding site of the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting the pump's activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production.
純度	99%
儲存/保存方法	Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
基本信息
可溶性/溶解性	10 mM in DMSO
生物活性
靶點(diǎn)	Proton pump
In vitro(體外研究)	Revaprazan Hydrochloride reversibly inhibits H+/K+-ATPase via binding to the K+-binding site of the pump. This reversibility leads to fewer adverse events. Revaprazan could inhibit H.pylori-induced COX-2 expression by blocking phosphorylation of IκB-α and Akt signaling in AGS cells. It could impose significant anti-inflammatory actions on H.pylori infection beyond acid suppression.
In vivo(體內(nèi)研究)	Pharmacokinetic studies of revaprazan hydrochloride in rats and dogs showed the drug had a low oral bioavailability, which was speculated to be due to first pass effect and poor water solubility of drug.
參考文獻(xiàn)
參考文獻(xiàn)	1. Lee JS, et al.J Clin Biochem Nutr. 2012 Sep;51(2):77-83. 2. Jung JW, et al. Tohoku J Exp Med. 2011;224(4):293-300.

研究領(lǐng)域
研究領(lǐng)域	MetabolismTypes of disease Drug DiscoverySmall Molecule DrugLead Compound Discovery

Revaprazan HCl 178307-42-1溫馨提示：本產(chǎn)品僅作科研實(shí)驗(yàn)使用，不支持臨床等研究

產(chǎn)品咨詢

留言框

產(chǎn)品：
您的單位：
您的姓名：
聯(lián)系電話：
常用郵箱：
省份：
詳細(xì)地址：
補(bǔ)充說明：
驗(yàn)證碼：

請輸入計(jì)算結(jié)果（填寫阿拉伯?dāng)?shù)字），如：三加四=7

上一篇：abs47028034Bromfenac sodium hydrate 120638-55-3
下一篇：abs47028036Cinacalcet hydrochloride 364782-34-3

Revaprazan HCl 178307-42-1

留言框

產(chǎn)品：

您的單位：

您的姓名：

聯(lián)系電話：

常用郵箱：

省份：

詳細(xì)地址：

補(bǔ)充說明：

驗(yàn)證碼：